– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that updated Phase 1a results from the ongoing FIT-001 Phase 1a/1b clinical trial (NCT06026410) evaluating darlifarnib in combination with cabozantinib in advanced renal cell carcinoma (RCC) will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit (KCRS) in Boston.

The presentation will highlight long-term follow-up results in heavily pretreated cabozantinib-naïve patients with refractory RCC, providing further evidence of darlifarnib’s potential as a combination agent with VEGFR-targeted therapies, a widely used treatment approach in this patient population. RCC is the most common form of kidney cancer, and clear cell RCC (ccRCC) is the most common histology in RCC, accounting for more than 61,000 new cases in the U.S. each year.